Key points from article :
Novo Nordisk has ended its collaboration with Japanese biotech Heartseed on a cell therapy for advanced heart failure, a deal that had been worth up to $598 million. The two companies had worked together since 2021 on HS-001, which uses clusters of heart muscle cells grown from induced pluripotent stem cells to try to restore heart muscle and function.
Under the original agreement, Novo paid $55 million upfront and in near-term milestones and held exclusive worldwide development and commercialisation rights outside Japan, where Heartseed kept its rights. All of the licensed intellectual property will now return to Heartseed. A phase 1/2 trial in 10 patients with severe heart failure finished at the end of July, but no results have been reported.
Novo cited "strategic reasons" for the decision, which comes as its new chief executive pushes a company-wide restructuring focused on diabetes and obesity that is expected to cut around 9,000 jobs. Heartseed said the termination had been "difficult to reasonably foresee" and would affect its future business strategy. The company plans to keep developing the therapy in Japan with its existing funds while it reviews its plans for overseas partners.
The move is a setback for Heartseed's plans to bring the stem cell therapy to patients outside Japan, although it reflects Novo's change in priorities rather than any reported problem with the treatment itself.


